Hanger Orthopedic Group Receives 510(k) Clearance

BETHESDA, Md., Feb. 2 /PRNewswire-FirstCall/ -- Hanger Orthopedic Group,

Inc. (NYSE: HGR) has announced its wholly-owned subsidiary Innovative

Neurotronics, Inc. (IN, Inc.) received 510(k) clearance from the U.S. Food and

Drug Administration (FDA) to treat patients with the WalkAide System(R).

The first of IN, Inc.'s line of functional electrical stimulation

products, the WalkAide System is a medical device designed to counter the lack

of ankle dorsiflexion, commonly referred to as foot drop, in patients who have

sustained damage to upper motor neurons or pathways to the spinal cord. The

WalkAide System electrically stimulates the appropriate nerves and muscles.

In addition to improving the patient's gait, medical benefits of the WalkAide

System may include increased mobility, prevention/retardation of disuse

atrophy, increased local blood flow, muscle re-education, and maintained or

increased joint range of motion.

"The commercial introduction of the WalkAide System will help us achieve

our vision of providing high technology products in the neuromuscular field by

leveraging Hanger's assets in distribution and patient care centers," Chairman

of the Board and Chief Executive Officer of Hanger Orthopedic Group, Inc. Ivan

R. Sabel, CPO said.

Hanger also announced today IN, Inc.'s newly-appointed management team,

led by President Jeff Martin.

"IN, Inc. has taken a significant step forward in its evolution by

receiving FDA approval and creating a management team with the talent and

depth of experience to advance our mission and expand the field of Myo-

Orthotics Technology(R)," Martin said.